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Promoting reproducibility in addiction research 
 
In recent years an energetic reproducibility debate has questioned whether published 
scientific findings are sufficiently robust. The field of addiction science should 
embrace this debate, and consider measures to improve the quality of the research it 
conducts. A manifesto has been published that suggests a number of possible 
measures to substantially reduce the bias towards unreliable positive findings. 
Addiction, as a key stakeholder already adopts many of the elements of this 
manifesto, and will continue to strengthen its policies in the future. 
 
Is there a reproducibility crisis in biomedical science? In 2005 Ioannidis 
argued that biases in how science is conducted and reported conspire to reduce the 
likelihood that published findings are reproducible (1). Since then, growing evidence 
has emerged that many key findings cannot be replicated. In 2011 scientists from the 
pharmaceutical company Bayer reported that they were only able to replicate ~25% 
of results published in the journals they looked at (2). Similar results have been 
reported by Amgen in 2012 (3) and more recently by the Reproducibility Project: 
Psychology (4). 
 A number of factors may serve to undermine the robustness of published 
findings. Small samples size is one (5, 6), and this appears to hold across the 
biomedical literature generally (7). What has been termed ‘herd behaviour’ may 
increase the risk that scientists will converge on an incorrect answer (8), while 
cognitive biases, such as confirmation bias and hindsight bias, together with a desire 
to be recognized, and secure research funding are also potential culprits. Some of 
these factors may not be directly causal, but instead point to problems with the 
current incentive structures within which scientists operate. For example, studies 
conducted in the US, where academic salaries are often not guaranteed if grant 
income is not generated, tend to over-estimate effects compared to studies 
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conducted outside the US (9), at least for the “softer” biomedical sciences (10). 
Studies published in journals with a high Impact Factor seem to be more likely to 
over-estimate effects (11). Indeed, journal Impact Factor appears to correlate more 
strongly with the likelihood of retraction than with the number of citations an article 
receives (12).  
 
INSERT TABLE 1 ABOUT HERE 
 
We recently published a Manifesto for Reproducible Science setting out a 
range of measures to optimize key elements of the scientific process: methods, 
reporting and dissemination, evaluation and incentives (13). These are shown in 
Table 1. Many of these measures can be adopted by individual researchers or 
research groups; others will require the engagement of key stakeholders – funders, 
journals and institutions. There may also be discipline-specific measures that can be 
taken – we recently outlined a range of measures intended to improve the reliability 
of findings generated by functional neuroimaging research (14). 
 Addiction has introduced a number of measures that align with those 
described in Table 1. These include encouraging authors to register hypotheses and 
analysis plans for all types of study (and requiring this for trials), requiring the use of 
CONSORT and other EQUATOR checklists for trials, encouraging authors to make 
data sets available, enforcing strict conflict of interest declarations, requiring authors 
to notify the journal of other articles that have been published or are planned that are 
based on the same data set as that being reported, and encouraging the use of the 
Open Science Framework (https://osf.io). 
 Ultimately, the issue is one of quality control. Science is perhaps like the US 
automobile industry in the 1970s, where productivity was high but quality control was 
poor (15). This was the era of the “lemon” – very low quality cars that were 
essentially built to be fixed later. The Japanese automobile industry took advice from 
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the US statistician Edwards Deming, and introduced the concept of quality control 
measures at every stage of the production pipeline. It still has a reputation for 
reliability today. We need to do something similar in the field of addiction and the 
journal, Addiction, will be at the forefront of this movement. 
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Table 1. A Manifesto for Reproducible Science. 
 
Theme Proposal Examples of initiatives/potential solutions (extent of current adoption) Stakeholder(s)  
Methods Protecting against 
cognitive biases 
All of the initiatives listed below (* to ****) 
Blinding (**) 
J, F 
Improving 
methodological training 
Rigorous statistical and research methods training of future researchers (*) 
Rigorous statistical and methods continuing education of researchers (*) 
I, F 
Independent 
methodological support 
Involvement of methodologists in research (**) 
Independent oversight (*) 
F 
Collaboration and team 
science 
Multi-site studies / distributed data collection (*) 
Team science consortia (*) 
I, F 
Reporting and 
Dissemination 
Promoting study pre-
registration 
Registered Reports (*) 
Open Science Framework (*) 
J, F 
Improving the quality of 
reporting 
Use of reporting checklists (**) 
Protocol checklists (*) 
J 
Protecting against 
conflicts of interest 
Disclosure of conflicts of interest (***) 
Exclusion/containment of financial and non-financial conflicts of interest (*) 
J 
Reproducibility Transparency and open 
science 
Open data, materials, software, etc. (* to **) 
Pre-registration (**** for clinical trials, * for other studies) 
J, F, R 
Evaluation Diversifying peer review Preprints (* in biomedical / behavioural sciences, **** in physical sciences) 
Pre- and post-publication peer-review, e.g. Publons, PubMed Commons (*) 
J  
Incentives Reward open, 
reproducible practices 
Badges (*) 
Registered Reports (*) 
Transparency and Openness Promotion guidelines (*) 
Funding replication studies (*) 
Open science practices in hiring and promotion (*) 
J, I, F 
 
Estimated extent of current adoption: * <5%, ** 5-30%, *** 30-60%, **** >60%; Abbreviations for key stakeholders: J: journals / publishers; I: 
institutions, F: funders, R: regulators. Reproduced with permission from Nature Human Behaviour (14). 
 
 
